Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,300.00
Bid: 12,300.00
Ask: 12,302.00
Change: -116.00 (-0.93%)
Spread: 2.00 (0.016%)
Open: 12,234.00
High: 12,300.00
Low: 12,164.00
Prev. Close: 12,416.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of AGM

29 Apr 2016 17:30

RNS Number : 9044W
AstraZeneca PLC
29 April 2016
 

ASTRAZENECA PLC - ANNUAL GENERAL MEETING 2016

 

Results of Annual General Meeting held on 29 April 2016

 

AstraZeneca PLC announced the results of the voting at its Annual General Meeting today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 1 - 8 were passed as ordinary resolutions and resolutions 9 - 11 were passed as special resolutions.

 

 

RESOLUTION

VOTES FOR

% OF VOTES CAST

VOTES AGAINST

% OF VOTES CAST

VOTES CAST IN TOTAL

TOTAL VOTES CAST AS A % OF ISSUED SHARE CAPITAL

VOTES WITHHELD

1

To receive the Company's Accounts and the Reports of the Directors and Auditor for the year ended 31 December 2015

 

924,514,473

99.61

3,665,459

0.39

928,179,932

73.40%

8,998,621

2

To confirm dividends

 

933,191,043

99.69

2,915,972

0.31

936,107,015

74.03%

1,071,537

3

To re-appoint KPMG LLP, London as Auditor

 

929,918,594

99.56

4,151,154

0.44

934,069,748

73.87%

3,108,804

4

To authorise the Directors to agree the remuneration of the Auditor

 

934,984,319

99.89

988,556

0.11

935,972,875

74.02%

1,204,865

5a

To re-elect Leif Johansson as a Director

 

861,678,834

94.69

48,321,545

5.31

910,000,379

71.96%

27,177,942

5b

To re-elect Pascal Soriot as a Director

 

935,167,473

99.93

697,471

0.07

935,864,944

74.01%

1,342,796

5c

To re-elect Marc Dunoyer as a Director

 

931,875,086

99.58

3,920,615

0.42

935,795,701

74.00%

1,380,982

5d

To re-elect Cori Bargmann as a Director

 

935,157,654

99.93

635,873

0.07

935,793,527

74.00%

1,384,110

5e

To re-elect Geneviève Berger as a Director

 

935,199,102

99.93

622,099

0.07

935,821,201

74.00%

1,356,436

5f

To re-elect Bruce Burlington as a Director

 

933,026,505

99.70

2,762,355

0.30

935,788,860

74.00%

1,389,088

5g

To re-elect Ann Cairns as a Director

 

933,220,149

99.72

2,618,183

0.28

935,838,332

74.01%

1,339,989

5h

To re-elect Graham Chipchase as a Director

 

919,686,570

98.97

9,526,012

1.03

929,212,582

73.48%

7,965,366

5i

To re-elect Jean-Philippe Courtois as a Director

 

933,177,891

99.72

2,593,420

0.28

935,771,311

74.00%

1,406,637

5j

To re-elect Rudy Markham as a Director

 

923,984,532

98.74

11,766,347

1.26

935,750,879

74.00%

1,427,442

5k

To re-elect Shriti Vadera as a Director

 

927,479,182

99.11

8,287,726

0.89

935,766,908

74.00%

1,410,552

5l

To re-elect Marcus Wallenberg as a Director

 

870,828,312

95.76

38,511,577

4.24

909,339,889

71.91%

27,837,158

6

To approve the Annual Report on Remuneration for the year ended 31 December 2015

836,396,151

89.61

96,959,428

10.39

933,355,579

73.81%

3,822,290

7

To authorise limited EU political donations

 

908,106,542

97.83

20,185,176

2.17

928,291,718

73.41%

8,886,009

8

To authorise the Directors to allot shares

 

849,809,843

90.97

84,303,774

9.03

934,113,617

73.87%

3,064,122

9

To authorise the Directors to disapply pre-emption rights

 

922,425,478

98.82

11,009,374

1.18

933,434,852

73.82%

3,742,888

10

To authorise the Company to purchase its own shares

 

926,166,577

98.96

9,722,078

1.04

935,888,655

74.01%

1,289,613

11

To reduce the notice period for general meetings

 

829,946,353

88.85

104,116,202

11.15

934,062,555

73.87%

3,115,081

 

 

 

Issued capital

As at 27 April 2016, the number of issued shares of the Company was 1,264,542,488 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.

 

 

A C N Kemp

Company Secretary

29 April 2016

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGPGUGACUPQGAB
Date   Source Headline
23rd Oct 20187:00 amRNSAstraZeneca Extends Innate Pharma Collaboration
22nd Oct 20187:00 amRNSLynparza shows 70% reduction in PFS ovarian cancer
19th Oct 20181:09 pmRNSCHMP positive opinion Bevespi Aerosphere
16th Oct 20187:00 amRNSFDA Orphan Drug for Lynparza in pancreatic cancer
1st Oct 20183:00 pmRNSTotal Voting Rights
1st Oct 20187:00 amRNSAtacand Agreement with Cheplapharm Completed
28th Sep 20184:00 pmRNSPrevious Announcement Regarding Appointment Of NED
25th Sep 20181:15 pmRNSOverall survival data for Imfinzi: Stage III NSCLC
24th Sep 20184:10 pmRNSEMA approves AZ's Imfinzi for Stage III NSCLC
24th Sep 20187:00 amRNSFarxiga gets positive result in DECLARE-TIMI 58
14th Sep 20187:00 amRNSFDA approves AZ's Lumoxiti in hairy cell leukaemia
7th Sep 20187:00 amRNSTezepelumab FDA Breakthrough Therapy Designation
6th Sep 20187:00 amRNSDirectorate Change
3rd Sep 20183:00 pmRNSTotal Voting Rights
31st Aug 20187:00 amRNSAstraZeneca Update on Anifrolumab in SLE
30th Aug 20187:00 amRNSEC approves Bydureon BCise device for T2 diabetes
23rd Aug 20187:00 amRNSAstraZeneca PIIIb trial update for Bevespi in COPD
21st Aug 20187:00 amRNSAZ's Tagrisso approved in Japan for 1st-line NSCLC
15th Aug 20187:00 amRNSAstraZeneca prices a $3bn bond issue
3rd Aug 20187:00 amRNSEMA grants OD for selumetinib in NF1
1st Aug 20183:00 pmRNSTotal Voting Rights
27th Jul 20182:00 pmRNSCHMP recommends Imfinzi for Stage III nsclc
26th Jul 20187:00 amRNSAZN: H1 2018 Results
24th Jul 20187:00 amRNSAtacand to be divested to Cheplapharm in Europe
18th Jul 20184:11 pmRNSHolding(s) in Company
18th Jul 201812:00 pmRNSHolding(s) in Company
2nd Jul 20183:00 pmRNSTotal Voting Rights
2nd Jul 20187:00 amRNSImfinzi approved in Japan for Stage III nsclc
2nd Jul 20187:00 amRNSLynparza approved in Japan for BRCAm breast cancer
29th Jun 20183:00 pmRNSBydureon receives positive CHMP opinion for BCise
28th Jun 20181:30 pmRNSAZ and Luye Pharma complete agreement for Seroquel
27th Jun 20187:00 amRNSLynparza: significant PFS 1st-line ovarian cancer
26th Jun 20187:00 amRNSBoard Committee Changes
22nd Jun 20187:00 amRNSPublication of a Prospectus
12th Jun 20187:00 amRNSUpdate: lanabecestat Phase III Alzheimer's trials
8th Jun 20185:30 pmRNSEU APPROVES TAGRISSO FOR 1ST-LINE NSCLC
8th Jun 20187:00 amRNSDirector Declaration
1st Jun 20183:00 pmRNSBlock listing Interim Review
1st Jun 20183:00 pmRNSTotal Voting Rights
1st Jun 201811:00 amRNSDirector Declaration
30th May 20187:00 amRNSUpdate on TERRANOVA PIII trial for Fasenra in COPD
25th May 20187:00 amRNSAZ's Imfinzi: significant OS in Stage III nsclc
21st May 20187:00 amRNSAZ regulatory submission in Japan for Forxiga
21st May 20187:00 amRNSUS FDA approves Lokelma for adult hyperkalaemia
18th May 20185:30 pmRNSResult of AGM
18th May 20187:00 amRNSAZN: Q1 2018 Results
11th May 20187:00 amRNSAstraZeneca update on Fasenra PIII trial in COPD
8th May 201811:00 amRNSEMA approves Lynparza: maintenance ovarian cancer
8th May 20187:00 amRNSAZ and Luye Pharma enter agreement for Seroquel
4th May 201812:00 pmRNSDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.